Apitope Strengthens Board with Senior Appointment

Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec

HASSELT, Belgium, and CHEPSTOW, UK, 7th March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced the appointment of William Jenkins, M.D., as Independent Non-Executive Director to its Board. Dr Jenkins has a wealth of pharmaceutical industry experience following a 30 year career in clinical medicine and research, and having served on several boards including Ablynx, BTG, Tanox, Evotec, Acambis and Consort Medical, and as chairman or member of several scientific advisory boards.

Commenting on the appointment, Stéphane Verdood, Chairman of the Board of Apitope, said:
“We are very pleased to welcome William to Apitope’s Board of Directors. William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first in class antigen-specific treatments targeted at autoimmune diseases, such as multiple sclerosis and Graves’ disease. William has advised companies through various stages of growth to maturity and in demanding situations. I know he will provide further strength and depth to the Apitope Board.”

Dr William Jenkins, Independent Non-Executive Director of Apitope, added:
“Autoimmune diseases affect a large and growing number of people, and can have extremely debilitating effects on their lives. I am excited by the potential of Apitope’s therapies and the impact they could make to patients around the world. I look forward to contributing to the Company’s advancement of these promising product candidates.”

Dr Jenkins has a wealth of pharmaceutical industry experience following a 30 year career in clinical medicine and research,. He has held senior posts at Glaxo as Head of Worldwide Clinical Research and at Ciba-Geigy and then Novartis as Global Head of Medicine, Clinical Development & Regulatory Affairs. During that time he was responsible for the development of drugs such as Zofran, Imigran, Serevent, Diovan & Gleevec. Since 1999, Dr Jenkins has been a consultant to the pharmaceutical industry and a member of several boards including Ablynx, BTG, Tanox, Monogram Biosciences, Eurand, Evotec, Acambis and Consort Medical, as well as a chairman or member of several scientific advisory boards.